Literature DB >> 3367156

31P nuclear magnetic resonance study of the brain in Alzheimer's disease.

J W Pettegrew1, J Moossy, G Withers, D McKeag, K Panchalingam.   

Abstract

The histopathological hallmarks of Alzheimer's disease have long been considered to be neurofibrillary tangles (NFT) and neuritic (senile) plaques (SP). Neither of these structures, however, are unique to Alzheimer's disease, and both probably represent end-stage markers of the disorder. NFT have been demonstrated in many disorders; SP occur in small numbers with normal aging. Evidence is presented for elevation of phosphomonoesters (PME) in Alzheimer's brain compared to non-Alzheimer's diseased controls and normal controls. The PME detected by 31P nuclear magnetic resonance (NMR) spectroscopy of autopsy brain are predominantly anabolic precursors of membrane phospholipids. Elevated PME could be secondary to a metabolic block at the rate-limiting enzyme in membrane phospholipid synthesis, which is cytidine triphosphate (CTP): phosphocholine (or phosphoethanolamine) cytidyltransferase (EC 2.7.7.15). Elevated PME could also be secondary to decreased breakdown of PME by phospholipase D activity. Since CTP: phosphocholine cytidyltransferase is inactivated by phosphorylation and since there is independent evidence for hyperphosphorylation of tau and MAP-2 proteins in AD brain, enhanced protein kinase activity could be a common factor. Preliminary evidence suggests that PME could interact with N-methyl-D-aspartate receptors and potentially act as false neurotransmitters. Further studies will be needed to investigate these possibilities.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3367156     DOI: 10.1097/00005072-198805000-00004

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  25 in total

Review 1.  Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens.

Authors:  A A Farooqui; S I Rapoport; L A Horrocks
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

Review 2.  Alzheimer disease--no target for statin treatment. A mini review.

Authors:  Siegfried Hoyer; Peter Riederer
Journal:  Neurochem Res       Date:  2006-10-25       Impact factor: 3.996

3.  Regional membrane phospholipid alterations in Alzheimer's disease.

Authors:  M R Prasad; M A Lovell; M Yatin; H Dhillon; W R Markesbery
Journal:  Neurochem Res       Date:  1998-01       Impact factor: 3.996

4.  Alzheimer's Abeta1-40 peptide modulates lipid synthesis in neuronal cultures and intact rat fetal brain under normoxic and oxidative stress conditions.

Authors:  N V Koudinova; A R Koudinov; E Yavin
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

5.  Regionally Distinct Alterations in Membrane Phospholipid Metabolism in Schizophrenia: A Meta-analysis of Phosphorus Magnetic Resonance Spectroscopy Studies.

Authors:  Connor S Haszto; Jeffrey A Stanley; Satish Iyengar; Konasale M Prasad
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-10-01

Review 6.  Alois Alzheimer revisited: differences in origin of the disease carrying his name.

Authors:  K Maurer; S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  2006-10-23       Impact factor: 3.575

7.  Neural membrane phospholipids in Alzheimer disease.

Authors:  K Wells; A A Farooqui; L Liss; L A Horrocks
Journal:  Neurochem Res       Date:  1995-11       Impact factor: 3.996

Review 8.  In vivo fatty acid incorporation into brain phospholipids in relation to signal transduction and membrane remodeling.

Authors:  S I Rapoport
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

Review 9.  Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.

Authors:  Evelin L Schaeffer; Orestes V Forlenza; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

10.  31P NMR of tissue phospholipids: competition for Mg2+, Ca2+, Na+ and K+ cations.

Authors:  T E Merchant; T Glonek
Journal:  Lipids       Date:  1992-07       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.